Researchers at the University of Cambridge have made a significant discovery regarding the potential effects of aspirin on cancer metastasis. In recent animal studies, scientists found that aspirin may enhance the immune system's ability to combat cancer cells that spread throughout the body. This finding could pave the way for future treatments involving aspirin for cancer patients, although experts caution against self-medication at this stage.
The study focuses on the process of metastasis, where cancer cells detach from a primary tumor and attempt to establish new growths elsewhere. The research indicates that while T-cells, a type of white blood cell, can attack these spreading cancer cells, platelets—cells that typically help with clotting—may inhibit T-cell activity. Aspirin appears to disrupt this platelet suppression, potentially allowing T-cells to function more effectively against metastasizing cancer.
Despite the promising nature of these findings, researchers emphasize the need for caution. Aspirin can pose risks, such as internal bleeding, and its efficacy may vary among different cancer types. Current clinical trials are underway to determine which patients might benefit most from aspirin post-cancer diagnosis and treatment. Notably, some individuals with conditions like Lynch syndrome, which increases cancer risk, may already be advised to take aspirin.
The research, which was published in the journal Nature, stemmed from a broader investigation into the immune response to cancer. While the discovery is seen as a key advancement in understanding aspirin's role in cancer treatment, further studies are needed before any definitive recommendations can be made regarding its use in cancer therapy.